Axovant Sciences Ltd Company Profile (NYSE:AXON)

About Axovant Sciences Ltd (NYSE:AXON)

Axovant Sciences Ltd logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer's disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company's pipeline also includes RVT-103 and RVT-104.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSE:AXON
  • CUSIP: N/A
  • Web: www.axovant.com/
Capitalization:
  • Market Cap: $2.68 billion
  • Outstanding Shares: 107,525,000
Average Prices:
  • 50 Day Moving Avg: $21.33
  • 200 Day Moving Avg: $21.33
  • 52 Week Range: $11.01 - $27.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.88
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.92 per share
  • Price / Book: 13.00
Profitability:
  • EBIDTA: ($207,250,000.00)
  • Return on Equity: -167.85%
  • Return on Assets: -104.54%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 6.01%
  • Quick Ratio: 6.01%
Misc:
  • Average Volume: 1.21 million shs.
  • Beta: 0.45
  • Short Ratio: 7.32
 

Frequently Asked Questions for Axovant Sciences Ltd (NYSE:AXON)

What is Axovant Sciences Ltd's stock symbol?

Axovant Sciences Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "AXON."

How were Axovant Sciences Ltd's earnings last quarter?

Axovant Sciences Ltd (NYSE:AXON) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by $0.12. View Axovant Sciences Ltd's Earnings History.

When will Axovant Sciences Ltd make its next earnings announcement?

Axovant Sciences Ltd is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Axovant Sciences Ltd.

Where is Axovant Sciences Ltd's stock going? Where will Axovant Sciences Ltd's stock price be in 2017?

11 brokerages have issued 12 month target prices for Axovant Sciences Ltd's stock. Their forecasts range from $7.50 to $40.00. On average, they anticipate Axovant Sciences Ltd's share price to reach $27.15 in the next year. View Analyst Ratings for Axovant Sciences Ltd.

What are analysts saying about Axovant Sciences Ltd stock?

Here are some recent quotes from research analysts about Axovant Sciences Ltd stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (7/11/2017)
  • 2. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences Ltd's key competitors?

Who are Axovant Sciences Ltd's key executives?

Axovant Sciences Ltd's management team includes the folowing people:

  • Marion McCourt, President, Chief Operating Officer
  • David T. Hung M.D., Chief Executive Officer, Director
  • Gregory M. Weinhoff M.D., Chief Financial Officer
  • Vivek Ramaswamy, Director, Chief Executive Officer - Roivant Sciences
  • Mark Altmeyer, President of Axovant Sciences GmbH and Chief Commercial Officer
  • Eric Floyd Ph.D., Senior Vice President - Regulatory Affairs
  • Ilise Lombardo M.D., Senior Vice President - Clinical Research
  • Thomas Templeman Ph.D., Senior Vice President - Pharmaceutical Operations and Quality Assurance
  • Mark Wadley, Senior Vice President, US Business
  • Samina Bari, Vice President - Corporate Communications

When did Axovant Sciences Ltd IPO?

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (6.74%), Capital Research Global Investors (3.25%), Janus Henderson Group PLC (1.94%), Franklin Resources Inc. (1.36%), State Street Corp (0.51%) and PointState Capital LP (0.33%). Company insiders that own Axovant Sciences Ltd stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences Ltd.

Who sold Axovant Sciences Ltd stock? Who is selling Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Franklin Resources Inc., VHCP Management II LLC, Artal Group S.A., Candriam Luxembourg S.C.A., Nationwide Fund Advisors, Ameriprise Financial Inc. and Strs Ohio. View Insider Buying and Selling for Axovant Sciences Ltd.

Who bought Axovant Sciences Ltd stock? Who is buying Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Capital Research Global Investors, State Street Corp, Ratan Capital Management LP, OxFORD Asset Management LLP, Prudential Financial Inc. and Federated Investors Inc. PA. Company insiders that have bought Axovant Sciences Ltd stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences Ltd.

How do I buy Axovant Sciences Ltd stock?

Shares of Axovant Sciences Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences Ltd's stock price today?

One share of Axovant Sciences Ltd stock can currently be purchased for approximately $24.96.


MarketBeat Community Rating for Axovant Sciences Ltd (NYSE AXON)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Axovant Sciences Ltd (NYSE:AXON) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $27.15 (8.77% upside)

Analysts' Ratings History for Axovant Sciences Ltd (NYSE:AXON)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$30.00HighView Rating Details
9/23/2017Chardan CapitalReiterated RatingSell$8.00HighView Rating Details
9/8/2017Evercore ISIInitiated CoverageOutperform -> Outperform$30.00HighView Rating Details
8/25/2017Jefferies Group LLCSet Price TargetBuy$40.00HighView Rating Details
6/21/2017Cowen and CompanyReiterated RatingOutperform$30.00MediumView Rating Details
6/14/2017CIBCBoost Price TargetOutperform -> Outperform$26.00 -> $30.00HighView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$32.00LowView Rating Details
2/14/2017HC WainwrightSet Price TargetBuy$35.00N/AView Rating Details
12/20/2016Robert W. BairdReiterated RatingPositive$29.00N/AView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
11/8/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Axovant Sciences Ltd (NYSE:AXON)
Earnings by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Earnings History by Quarter for Axovant Sciences Ltd (NYSE AXON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.58)N/AView Earnings Details
10/23/2017N/AView Earnings Details
8/7/2017Q1 2018($0.53)($0.65)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axovant Sciences Ltd (NYSE:AXON)
Current Year EPS Consensus Estimate: $-2.33 EPS
Next Year EPS Consensus Estimate: $-2.81 EPS

Dividends

Dividend History for Axovant Sciences Ltd (NYSE:AXON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axovant Sciences Ltd (NYSE:AXON)
Insider Ownership Percentage: 72.50%
Insider Trades by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Institutional Ownership by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Insider Trades by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.98View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Axovant Sciences Ltd (NYSE:AXON)
Latest Headlines for Axovant Sciences Ltd (NYSE:AXON)
Source:
DateHeadline
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 25 at 4:44 PM
americanbankingnews.com logoFinancial Contrast: Axovant Sciences (AXON) & Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - September 25 at 6:32 AM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - September 23 at 4:46 PM
nasdaq.com logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON ... - Nasdaq
www.nasdaq.com - September 23 at 4:16 PM
americanbankingnews.com logoChardan Capital Reiterates Sell Rating for Axovant Sciences Ltd (AXON)
www.americanbankingnews.com - September 23 at 2:56 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 23 at 9:10 AM
fool.com logo3 Biotech Stocks With Major Catalysts Incoming -- The Motley Fool - Motley Fool
www.fool.com - September 22 at 8:14 PM
finance.yahoo.com logoTraders expect an 80% move for this hot biotech stock in the next month
finance.yahoo.com - September 22 at 3:11 PM
nasdaq.com logoInsiders Seeing Green With AXON At New 52-Week High
www.nasdaq.com - September 22 at 12:56 PM
finance.yahoo.com logoVenturing Boldly Into Neuroscience
finance.yahoo.com - September 22 at 12:56 PM
finance.yahoo.com logo3 Biotech Stocks With Major Catalysts Incoming
finance.yahoo.com - September 22 at 12:56 PM
finance.yahoo.com logoAxovant Sciences Shows Rising Price Performance With Jump To 93 RS Rating
finance.yahoo.com - September 19 at 4:16 PM
finance.yahoo.com logoAxovant Sciences Ltd. (AXON) Jumps: Stock Rises 7.2%
finance.yahoo.com - September 19 at 4:16 PM
thestreet.com logoNotable Monday Option Activity: AXON, OA, AST
www.thestreet.com - September 18 at 4:40 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Downgraded by BidaskClub
www.americanbankingnews.com - September 16 at 6:32 PM
seekingalpha.com logoAxovant Sciences: The Progressively Contentious Alzheimer's Claim
seekingalpha.com - September 14 at 4:54 PM
americanbankingnews.com logoAxovant Sciences' (AXON) Sell Rating Reiterated at Chardan Capital
www.americanbankingnews.com - September 14 at 12:28 PM
finance.yahoo.com logoAxovant Sciences Joins Elite Club Of Stocks With RS Ratings Over 90
finance.yahoo.com - September 12 at 9:31 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Axovant Sciences ... - Nasdaq
www.nasdaq.com - September 12 at 2:53 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock?
finance.yahoo.com - September 11 at 4:48 PM
nasdaq.com logoNoteworthy Friday Option Activity: REGN, FNHC, AXON
www.nasdaq.com - September 8 at 4:39 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - September 8 at 10:46 AM
finance.yahoo.com logoAxovant to Present at Two Upcoming Investor Conferences
finance.yahoo.com - September 6 at 4:10 PM
finance.yahoo.com logoToday's Bell Ringer, September 6, 2017
finance.yahoo.com - September 6 at 4:10 PM
benzinga.com logoOppenheimer Presents New Menu Of Top Picks - Benzinga
www.benzinga.com - September 1 at 3:24 PM
finance.yahoo.com logoQVT Financial’s Investments, Performance, Letters
finance.yahoo.com - August 30 at 5:31 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 29 at 8:44 AM
seekingalpha.com logoAxovant Sciences: The Contentious Alzheimer's Claim
seekingalpha.com - August 28 at 4:18 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Given a $40.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - August 26 at 11:02 AM
nasdaq.com logoNoteworthy Wednesday Option Activity: AXS, KITE, AXON
www.nasdaq.com - August 23 at 4:25 PM
finance.yahoo.com logoAxovant to Move Stock Exchange Listing to Nasdaq
finance.yahoo.com - August 23 at 4:25 PM
reuters.com logoBRIEF-Axovant to move stock exchange listing to Nasdaq - Reuters
www.reuters.com - August 22 at 2:24 AM
reuters.com logoBRIEF-Axovant to move stock exchange listing to Nasdaq
www.reuters.com - August 21 at 9:22 PM
americanbankingnews.com logoZacks: Analysts Expect Axovant Sciences Ltd. (AXON) to Announce -$0.58 EPS
www.americanbankingnews.com - August 21 at 10:24 AM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - August 19 at 8:30 PM
americanbankingnews.com logoAxovant Sciences Target of Unusually High Options Trading (AXON)
www.americanbankingnews.com - August 19 at 1:32 AM
nasdaq.com logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock - Nasdaq
www.nasdaq.com - August 18 at 9:24 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Axovant Sciences (AXON) Stock
finance.yahoo.com - August 18 at 4:23 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Axovant Sciences Ltd.
finance.yahoo.com - August 10 at 4:24 PM
finance.yahoo.com logoRoivant's Billion-Dollar Haul Shouldn't Buy Off Skepticism
finance.yahoo.com - August 10 at 4:24 PM
finance.yahoo.com logo[$$] SoftBank Leads $1.1 Billion Investment in Roivant Sciences
finance.yahoo.com - August 9 at 9:31 PM
finance.yahoo.com logoBiotech Wunderkind Raises $1.1 Billion To Fund Pharma Startups
finance.yahoo.com - August 9 at 4:28 PM
finance.yahoo.com logoA 32-year-old biotech CEO just raised $1.1 billion from SoftBank to give old drugs new life
finance.yahoo.com - August 9 at 4:28 PM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Posts Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - August 8 at 10:51 AM
finance.yahoo.com logoAxovant Announces Fiscal First Quarter Financial Results and Corporate Updates
finance.yahoo.com - August 7 at 5:03 PM
finance.yahoo.com logoAxovant reports 1Q loss
finance.yahoo.com - August 7 at 5:03 PM
americanbankingnews.com logoAxovant Sciences Ltd. (AXON) to Release Earnings on Monday
www.americanbankingnews.com - August 7 at 7:50 AM
americanbankingnews.com logoAxovant Sciences Ltd. (NYSE:AXON) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 8:52 AM
americanbankingnews.com logo Analysts Expect Axovant Sciences Ltd. (AXON) to Announce -$0.52 Earnings Per Share
www.americanbankingnews.com - August 3 at 8:08 AM
finance.yahoo.com logoWill Axovant Catch Lightning in a Bottle With Its Alzheimer's Drug?
finance.yahoo.com - July 26 at 4:53 PM

Social

Chart

Axovant Sciences Ltd (AXON) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff